Bristol-Myers Squibb Deploys Anthropic Claude AI to 30,000 Employees for Drug Discovery
Bristol-Myers Squibb is deploying Anthropic’s Claude AI model to over 30,000 employees across research, development and commercial teams to accelerate drug discovery workflows. The program will integrate generative AI into target identification, hit optimization and project decision-making to reduce R&D costs and shorten development timelines.
1. Partnership with Anthropic
Bristol-Myers Squibb has entered into a strategic collaboration with AI developer Anthropic to leverage its Claude large language model across the company. The agreement grants BMS access to Claude’s generative capabilities for scientific research, data analysis and decision support, positioning AI as a core component of its innovation strategy.
2. Deployment Scale and Objectives
The rollout will cover more than 30,000 employees in R&D, regulatory, safety and commercial functions. By embedding Claude in daily workflows, BMS intends to streamline hypothesis generation, accelerate target validation and enhance cross-functional collaboration.
3. Expected Impact on Drug Discovery
Integrating Claude aims to reduce time-to-lead and time-to-candidate stages by automating literature reviews, in silico screening and experimental design. BMS projects that AI-driven insights will lower R&D expenditures and improve hit-to-lead success rates, strengthening its mid- and late-stage pipeline.
4. Implementation Timeline and Future Plans
Initial deployment begins in the third quarter with pilot groups in oncology and immunology research teams, followed by broader adoption through year-end. Success metrics will include reductions in cycle times, cost per assay and internal satisfaction scores, with plans to expand Claude’s use into clinical development support.